Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Account Payables (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Change in Account Payables for 14 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 293.11% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.1 million through Dec 2025, up 1340.99% year-over-year, with the annual reading at $25.1 million for FY2025, 1340.99% up from the prior year.
  • Change in Account Payables hit $6.0 million in Q4 2025 for Corcept Therapeutics, down from $10.9 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $12.9 million in Q1 2025 to a low of -$4.9 million in Q1 2024.
  • Historically, Change in Account Payables has averaged $1.5 million across 5 years, with a median of $99500.0 in 2021.
  • Biggest five-year swings in Change in Account Payables: plummeted 1110.27% in 2021 and later soared 5303.03% in 2023.
  • Year by year, Change in Account Payables stood at $364000.0 in 2021, then surged by 1065.38% to $4.2 million in 2022, then crashed by 84.98% to $637000.0 in 2023, then crashed by 587.6% to -$3.1 million in 2024, then skyrocketed by 293.11% to $6.0 million in 2025.
  • Business Quant data shows Change in Account Payables for CORT at $6.0 million in Q4 2025, $10.9 million in Q3 2025, and -$4.8 million in Q2 2025.